OBJECTIVES:: Demonstrate the financial impact of using the sFlt-1/PlGF ratio test for guiding the management of preeclampsia at Brazilian private perspective. METHODS:: A budget impact model was adapted based on decision-tree model which compares the costs in a current standard of care scenario “no test” and a “test scenario” adding the sFlt-1/PlGF test to current standard of care for a cohort of 1000 pregnant women with clinical suspicion of Preeclampsia (signs and/or symptoms) from 20 to 40 gestational weeks. The time horizon was 1 year and a one-way sensitivity analysis was performed. Besides of that, test characteristics were derived from PROGNOSIS study, a non-interventional study in women presenting with clinical suspicion of pre-eclampsia and the costs are from a Brazilian private hospital, considering patients from Health Insurances. RESULTS:: The sFlt-1/PlGF ratio can improve prediction and management of preeclampsia. The economic model suggests that adding the test could reduce unnecessary interventions and, as a consequence, generate a cost saving of approximate 635,84 BRL per patient. A one-way sensitivity analysis revealed that cost saving are robust to plausible changes in the main parameters. CONCLUSIONS:: Enhanced prediction of preeclampsia using the sFlt-1/PlGF ratio could improve clinical management for pregnant women, ensuring the most appropriate care for the ones with higher risk and reduce the costs associated with unnecessary interventions.